Rapid Medical Expands U.S. Portfolio

Rapid Medical is expanding its U.S. portfolio through an exclusive distribution agreement with MicroPort NeuroTech, a subsidiary of MicroPort Scientific Corporation. MircoPort’s global presence offers nearly 300 medical solutions to patients in more than 80 countries and generates more than $780 million in annual revenue.
 
The Numen Coil Embolization System showed excellent results in a 350-patient, prospective head-to-head study against one of the market-leading coils.¹ In the trial, the Numen coil demonstrated 91.2% successful long-term occlusion at six months and comparable mortality and serious adverse events. These results are particularly noteworthy since the Numen coils are generally longer and may need fewer coils to achieve the same packing density.
 
“We are excited to expand our portfolio for treating brain aneurysms with the addition of the Numen Coil Embolization System,” commented James Romero, president, Americas of Rapid Medical. “The combination of our de Novo Comaneci device and the Numen coil expands physicians’ capabilities to treat complex aneurysms with one of the safest and most effective modalities available–Comaneci-assisted coil embolization.”
 
“This strategic partnership leverages the strengths of both companies and our respective products,” said Bruce Wang, executive director and executive vice president of MicroPort NeuroTech and Rapid Medical board member. “By working together, we can offer physicians superior options for successful outcomes.”

“The Numen coils are extremely soft and take the shape of the anatomy very well,” said Dr. Ajit Puri, who completed a Numen coil embolization procedure at UMASS Memorial Hospital in Worcester, Mass. “The reliability from shape to detachment is exactly what we are looking for when choosing a coil.”
 
Rapid Medical develops responsive interventional devices for neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER 17 and 21, COMANECI, and COLUMBUS/DRIVEWIRE are CE marked and cleared by the U.S. Food and Drug Administration.  TIGERTRIEVER 13 and XL are also CE marked. 

Reference 
¹ Zhao R, Duan G, Yang P, et al. Endovascular Aneurysm Treatment with the Numen Coil Embolization System: A Prospective Randomized Controlled Open-Label Multicenter Noninferiority Trial in China. World Neurosurg. 2022;160:e23-e32. doi:10.1016/j.wneu.2021.11.067